| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000036835 |
| Receipt No. | R000041964 |
| Scientific Title | DAA therapy and ADAMTS13/VWF for HCV |
| Date of disclosure of the study information | 2020/01/01 |
| Last modified on | 2019/05/23 (Ver. 1) |
| Basic information | ||
| Public title | DAA therapy and ADAMTS13/VWF for HCV | |
| Acronym | DAA therapy and ADAMTS13/VWF for HCV | |
| Scientific Title | DAA therapy and ADAMTS13/VWF for HCV | |
| Scientific Title:Acronym | DAA therapy and ADAMTS13/VWF for HCV | |
| Region |
|
|
| Condition | ||
| Condition | hepatitis type C | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate whether ADAMTS13/VWF is associated with functional liver capacity for hepatitis C patients receiving DAA therapy |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Portal hypertension |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)> 20 years old
2)The patients obtained the consent |
|||
| Key exclusion criteria | 1)The impossible of oral intake
2)The pharmacokinetics is changed for patient's condition 3)The necessary medicine change the pharmacokinetics of rifaximin 4)The pregnancy and lactating 5)The allergy of rifaximin 6)The outcome evaluation is difficult for patient's condition 7)The execution plan of achievement is difficult |
|||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Nara medical unversity | ||||||
| Division name | 3rd departemnt of interanal medicine | ||||||
| Zip code | 6348521 | ||||||
| Address | 840, Shijo-cho, Kashihara, Nara | ||||||
| TEL | 0744223051 | ||||||
| htky@naramed-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Nara medical unversity | ||||||
| Division name | 3rd departemnt of interanal medicine | ||||||
| Zip code | 6348521 | ||||||
| Address | 840, Shijo-cho, Kashihara, Nara | ||||||
| TEL | 0744223051 | ||||||
| Homepage URL | |||||||
| htky@naramed-u.ac.jp | |||||||
| Sponsor | |
| Institute | Nara Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Developmen |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Nara medical unversity |
| Address | 840, Shijo-cho, Kashihara, Nara |
| Tel | 0744223051 |
| htky@naramed-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | nothing |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041964 |